Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eniluracil - Processa Pharmaceuticals

Next Previous
Drug Profile

Eniluracil - Processa Pharmaceuticals

Alternative Names: 5-Ethynyluracil; 5-EU; 776C85; ADH 300004; GW 776C85; NGC-Cap; NGC-Capecitabine; PCS-6422

Latest Information Update: 28 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Adherex Technologies; Fennec Pharmaceuticals; GlaxoSmithKline; Processa Pharmaceuticals
  • Class Antineoplastics; Chemosensitisers; Pyrimidinones; Small molecules
  • Mechanism of Action Dihydropyrimidine dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Colorectal cancer; Liver cancer; Pancreatic cancer; Solid tumours
  • No development reported Chemotherapy-induced damage; Gastrointestinal cancer
  • Discontinued Erythrodysaesthesia; Head and neck cancer; Prostate cancer

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for preclinical development in Chemotherapy-induced-damage in USA (PO)
  • 28 Sep 2024 No recent reports of development identified for preclinical development in Colorectal-cancer(Combination therapy) in USA (PO)
  • 09 Sep 2024 Processa Pharmaceuticals completes a phase-I clinical trials in Gastrointestinal cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT04861987)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top